SOUTH WINDSOR, CT - January 28, 2009 - Gerber Scientific, Inc. (NYSE: GRB), a worldwide leader in integrated automation solutions for the sign making, specialty graphics and other industries, announced today that it has granted a patent license to Graphtec Corporation, a leading global plotter and printer manufacturer. This license represents the third non-exclusive license Gerber has granted to a Japanese equipment manufacturer for its family of computerized “print to cut” technology patents, based off of its pioneering U.S. Patent 5,537,135. Financial and other terms of the license agreement were not disclosed.

“We are very pleased to have concluded an agreement with Graphtec Corporation, enabling it to utilize our patented technology within its suite of plotter and printer products. This action is another example of Gerber’s stated position of allowing other companies access to this family of patents to advance the industry as a whole.” said Marc T. Giles, President and CEO of Gerber Scientific, Inc.

Gerber is presently prosecuting an action for infringement of the ‘135 Patent in the Hartford, CT Federal District Court against Roland DGA Corporation, the distribution and sales arm of Roland DG Corporation of Hamamatsu, Japan. The Company is seeking damages and an injunction against Roland's sale of infringing products. The law suit is currently in the discovery phase, awaiting the setting of a trial date by the court.

About Gerber Scientific, Inc.
Gerber Scientific, Inc. (www.gerberscientific.com) is a leading international supplier of sophisticated automated manufacturing systems for sign making, specialty graphics, and packaging, apparel and flexible materials, and ophthalmic lens processing industries. Headquartered in South Windsor, Connecticut, the company operates through four businesses: Gerber Scientific Products and Spandex Ltd., Gerber Technology, and Gerber Coburn.

Forward-looking Statements:
This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements contained in this news release regarding product launches and benefits are forward-looking statements that involve risks and uncertainties. For information identifying other important economic, political, regulatory, legal, technological, competitive and other uncertainties, readers are referred to the Company’s filings with the Securities and Exchange Commission, including but not limited to, the information included in Gerber Scientific’s Annual Report on Form 10-K for the fiscal year ended April 30, 2008 under the headings “Business,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Cautionary Note Concerning Factors That May Influence Future Results,” as well as information included in subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, which outline certain important risks regarding the Company’s forward-looking statements. These risks include, but are not limited to, delays in the Company’s new product development and commercialization, intense competition in markets for each of the Company’s operating segments, rapid technological advances, availability and cost of raw materials, volatility in foreign currency exchange rates and fluctuations in interest rates. Actual future results or events may differ materially from these forward-looking statements. The Company expressly disclaims any obligation to update any of these forward-looking statements, except as required by law.